Invention Grant
- Patent Title: Methods of treating metabolic disorders with dual function fibroblast growth factor 21 proteins
-
Application No.: US15248712Application Date: 2016-08-26
-
Publication No.: US10669323B2Publication Date: 2020-06-02
- Inventor: Brian R. Boettcher , Shari Lynn Caplan , Susan E. Cellitti , Douglas S. Daniels , Norio Hamamatsu , Bernhard Hubert Geierstanger , Stuart Licht , Andreas Loew , Stephen Craig Weldon
- Applicant: Brian R. Boettcher , Shari Lynn Caplan , Susan E. Cellitti , Douglas S. Daniels , Norio Hamamatsu , Bernhard Hubert Geierstanger , Stuart Licht , Andreas Loew , Stephen Craig Weldon
- Applicant Address: CH Basel
- Assignee: NOVARTIS AG
- Current Assignee: NOVARTIS AG
- Current Assignee Address: CH Basel
- Agent Yichen Liu
- Main IPC: A61K38/18
- IPC: A61K38/18 ; A61K38/26 ; C07K14/605 ; C07K14/50
Abstract:
The present invention relates to the identification of dual function fusion proteins comprising fibroblast growth factor 21 (FGF21) and Exenatide, Exendin-4, or GLP-1. Also disclosed are methods for treating metabolic, cardiovascular, and endocrine conditions related to glucose and/or lipid homeostasis.
Public/Granted literature
- US20170166621A1 DUAL FUNCTION PROTEINS FOR TREATING METABOLIC DISORDERS Public/Granted day:2017-06-15
Information query
IPC分类:
